Evotec and Lilly to collaborate in metabolic diseases
German Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes.
Protagen, BioAnalytix and GeneWerk launch ProtaGene
Following their last year announcement to merge, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launch a CRO named ProtaGene.
BioNTech SE licences Cresendo Bios Humabody technology
BioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies .
Novartis AG executes licence option with Molecular Partners
After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.
Neurimmune inks US-$760 deal with AstraZeneca
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Santhera finds Chinese marketing partner for vamorolone
Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
DNA Script bags US$200m financing
Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Sound Bioventures Fund I AB closes at 110m
Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put 110m in the first fund of Sound Bioventures AB.
Omicron variant more harmless than Delta
The new year begins with good news.
Season Greetings
Merry Christmas and a Happy New Year!